Highlights

  • EBR Systems (ASX:EBR) has secured ISO 13485 certification for its expanded Santa Clara Manufacturing facility.
  • New automated assembly equipment is expected to increase WiSE System production capacity by approximately 500% once the Facility receives FDA approval.
  • The expanded manufacturing platform is designed to support the continuing US commercial rollout and improve production efficiency.
  • Implant growth, hospital adoption, manufacturing scale-up and regulatory approvals remain central to the company’s commercial execution.

EBR Systems (ASX:EBR) is moving deeper into the commercialisation phase of its WiSE CRT System, with a fresh manufacturing milestone adding another component to its scale-up strategy. The US-based, ASX-listed medical technology company has developed a wireless endocardial pacing system designed for heart-failure patients who cannot be treated adequately with conventional cardiac resynchronisation therapy.

On 7 September 2026, EBR announced that its new manufacturing facility in Santa Clara, California, had achieved ISO 13485 certification following assessment by the British Standards Institution. The certification represents an important quality-management milestone for medical-device production and clears another step in EBR’s transition toward a larger and more scalable manufacturing platform.

The development comes as the company continues converting its regulatory progress into commercial adoption. The most recent implant data came in the June-quarter update released on 12 August 2026, when EBR reported that it had passed its 117th cumulative commercial implant after crossing the 100-implant mark during the quarter ended 30 June 2026. That followed the March-quarter update, when the company recorded 41 US implants, approximately US$2.4 million of revenue, 71 cumulative commercial implants, 55 trained physicians and 16 new purchase agreements.

Manufacturing scale-up gains momentum

The latest development materially strengthens EBR Systems’ (ASX:EBR) manufacturing infrastructure. The company has installed additional equipment at the Santa Clara facility, including automated assembly machinery intended to support the transition away from a more manual manufacturing process.

Once regulatory approval for the facility is obtained, EBR expects the new assembly setup to increase WiSE System production capacity by approximately 500%. The shift is also intended to improve manufacturing efficiency, reduce costs and lift production yields as commercial Demand grows.

The larger facility is therefore not simply an infrastructure upgrade. It forms part of EBR’s broader strategy to ensure that manufacturing capacity can keep pace with the expanding US rollout of WiSE.

The next regulatory milestone for the facility is an FDA Pre-Approval Inspection scheduled for September 2026. Subject to completion of that process and the resolution of any observations that may arise, EBR expects FDA approval for the facility by the end of 2026.

Building the commercial base

EBR Systems (ASX:EBR) is continuing a controlled Limited Market Release, prioritising physician Training and hospital onboarding while gradually expanding implant activity. Its August update highlighted purchasing agreements with major US health systems, including HCA Healthcare, Advocate Health and CHRISTUS Health, alongside additional agreements with targeted treatment centres.

Access to large hospital networks matters because cardiac resynchronisation therapy involves specialist referral pathways, physician credentialing and institutional purchasing processes. Once a hospital and its clinicians are trained and approved to use WiSE, successful early procedures can potentially translate into repeat implant activity.

The latest manufacturing progress complements that commercial groundwork. As the company expands its network of trained physicians and purchasing agreements, production capability increasingly becomes an important part of the scale-up equation.

Balance-sheet strength supports expansion

EBR reported cash, cash equivalents, restricted cash and marketable securities of US$89.5 million, equivalent to approximately A$130.1 million, at 30 June 2026. This followed a fully underwritten A$150 million Capital raising that materially strengthened its financial position.

Earlier in 2026, the company held approximately US$33.5 million at 31 March. The additional funding therefore provided EBR with greater flexibility to invest in manufacturing capacity, commercial infrastructure, physician training and broader US market development. The company also completed a one-for-ten share consolidation during the period.

The stronger funding position is particularly relevant as EBR moves from early commercial adoption toward a more capital-intensive phase involving higher production capacity and wider hospital penetration.

Why it matters and what to watch

For investors, EBR Systems (ASX:EBR) combines a differentiated medical device with a defined clinical need and first-mover regulatory positioning in the US. The WiSE System is designed to remove the need for a traditional coronary sinus pacing lead when stimulating the left ventricle, potentially addressing some of the limitations associated with conventional CRT systems.

The new ISO-certified manufacturing facility strengthens the operational side of the commercialisation story. If FDA approval of the site is achieved as anticipated, the transition toward automated assembly could allow EBR to support materially higher volumes while improving production economics.

Several catalysts now sit ahead. Investors will be watching the FDA inspection and potential approval of the new Santa Clara facility, the ramp-up of automated production, quarterly implant growth, Revenue progression and broader adoption across newly contracted health systems.

Progress in Australia also remains relevant after EBR secured a Priority Review Determination from the Therapeutic Goods Administration, which could support a future pathway toward inclusion on the Australian Register of Therapeutic Goods.

The risks remain significant. EBR is still loss-making and cash-consumptive as it invests in manufacturing, sales infrastructure and clinician training. Adoption of novel implantable medical devices can also take time, while reimbursement processes, hospital approvals, procedure scheduling and physician confidence can all influence the pace of commercial expansion.

A balanced view

EBR Systems (ASX:EBR) is increasingly shifting from a regulatory story toward an execution and scale-up story. FDA approval of WiSE established the commercial opportunity, while rising implant numbers and hospital agreements have begun to demonstrate early market adoption.

The ISO 13485 certification achieved on 7 September 2026 adds another important piece by strengthening the manufacturing foundation needed to support substantially higher production volumes. The planned move toward automated assembly and an approximately 500% increase in production capacity could become increasingly important if commercial demand continues to build.

The next phase will depend on EBR successfully completing the FDA facility approval process, converting hospital agreements into sustained implant activity and translating higher manufacturing capacity into stronger revenue growth. If those elements progress together, the company could move closer to demonstrating that WiSE is not only a clinically differentiated technology but also a scalable commercial platform.